Honghui Hu of Wanhuida Intellectual Property explains that a CNIPA ruling on a patent covering an antidepressant could help to determine the patentability of pharmaceutical compounds
The top ten patent reexamination and invalidation cases in 2022 include 8 invalidation cases of invention patents, 1 invalidation case of a utility model patent and 1 invalidation case of a design patent.
Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees
Polymorphism of a pharmaceutical compound refers to its state of existing in different solid forms that is caused by the fact that the molecules of the compound, though being of the.
Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees